Skip to main content
OpenTrials
Completed

NCT Number: NCT02201134

SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia

Studying the feasibility of an initial sedation with inhalated sevoflurane during therapeutic hypothermia of cardiac arrests resuscitated patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiac Arrest Cardiovascular Diseases Heart Arrest Heart Diseases Therapeutic Hypothermia

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Clermont-Ferrand

Clermont-Ferrand, 63003, France

About this study

Prospective clinical study in ICU with ventilated patients sedated with sevoflurane using the Mirus® and Anaconda® , establishing the feasibility of an initial sedation of patients resuscitated from cardiac arrest and treated with therapeutic hypothermia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • -Adult patients ventilated requiring therapeutic hypothermia in ICU
  • Stable respiratory and hemodynamic conditions
  • Epinephrine and norepinephrine infusion rate < 1,5 g/kg/min
  • Consent of patients or family
  • Arterial line
  • Patients resuscitated after cardiac arrest
  • No Flow < 10 min
  • Low Flow < 20 min
  • Neutropenia < 1 G/L
  • Post traumatic cardiac arrest
  • Contraindication of halogenated anesthesics
  • Extra corporeal life support or intra aortic balloon pump

Exclusion criteria

  • -Pregnant woman
  • Hemodynamic instability
  • Brain death defined by the disappearance of brain stem reflexes

Treatment and study plan

Sevoflurane

Drug

Primary outcomes

  1. Determination of the feasibility of a sedation with inhalated sevoflurane in cardiac arrest resuscitated patients

    Time frame: at day 1

    The feasibility is evaluated by the number of side effects due to treatment until discharge from hospital.

Secondary outcomes

  1. Determination of neurological prognostic of patients at ICU and hospital discharge

    Time frame: at day 1

  2. Determination of systemic complications and organ failures during hospitalisation

    Time frame: at day 1

  3. Evaluation of systemic inflammation and evolution with cytokines

    Time frame: at day 1

  4. Evaluation of markers specific of brain ischemia (S100 protein and neuron-specific enolase)

    Time frame: at day 1

    at 3 times: before starting sevoflurane sedation, 24 hours, 48 hours and 72 hours after starting sevoflurane sedation.

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Collaborators

  • Hopital Gabriel Montpied
  • University Hospital, Estaing

Registry information

Acronym: SEVOCAR

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Jul 25, 2014
Registry last updated
Jul 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.